PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9822653-5 1998 We found that CREB (cAMP response element-binding protein) binding protein (CBP) had a direct role in both of these activities of AR. Cyclic AMP 20-24 androgen receptor Homo sapiens 130-132 10779504-0 2000 p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. Cyclic AMP 14-18 androgen receptor Homo sapiens 84-101 10779504-3 2000 p300 and p300/cAMP-response element-binding protein acetylated the AR at a highly conserved lysine-rich motif carboxyl-terminal to the zinc finger DNA-binding domain. Cyclic AMP 14-18 androgen receptor Homo sapiens 67-69 10779504-6 2000 Mutation of the p300 CH3 region or the p300/cAMP-response element-binding protein histone acetylase domain reduced ligand-dependent AR function. Cyclic AMP 44-48 androgen receptor Homo sapiens 132-134 10730903-6 1999 In the absence of androgen, a compensatory increase in the activity of cAMP-dependent protein kinase (PKA) enhances the ability of the androgen receptor to bind to the response elements regulating PSA gene expression. Cyclic AMP 71-75 androgen receptor Homo sapiens 135-152 11429409-6 2001 AR dramatically increased the intrinsic transcriptional activity of the nuclear receptor coactivators glucocorticoid receptor-interacting protein-1 (GRIP1), cAMP response element-binding protein-binding protein, and p300 that are tethered to DNA. Cyclic AMP 157-161 androgen receptor Homo sapiens 0-2 9280065-6 1997 Instead, two other elements within the promoter-regulatory region (alpha-basal element and cAMP-regulatory element), which are important for expression of the alpha-subunit gene in gonadotropes, mediate the effects of AR. Cyclic AMP 91-95 androgen receptor Homo sapiens 218-220 9280065-7 1997 This suggests that AR inhibits activity of the alpha-subunit promoter by interfering with the transcriptional properties of the proteins that bind to alpha-basal element and the cAMP-regulatory elements. Cyclic AMP 178-182 androgen receptor Homo sapiens 19-21 9215398-1 1997 BACKGROUND: We investigated modulation of androgen receptor (AR) activity in prostatic tumor cells by luteinizing hormone-releasing hormone (LHRH)-induced increase of the intracellular cyclic adenosine monophosphate (cAMP) level. Cyclic AMP 185-215 androgen receptor Homo sapiens 42-59 9215398-1 1997 BACKGROUND: We investigated modulation of androgen receptor (AR) activity in prostatic tumor cells by luteinizing hormone-releasing hormone (LHRH)-induced increase of the intracellular cyclic adenosine monophosphate (cAMP) level. Cyclic AMP 185-215 androgen receptor Homo sapiens 61-63 9215398-1 1997 BACKGROUND: We investigated modulation of androgen receptor (AR) activity in prostatic tumor cells by luteinizing hormone-releasing hormone (LHRH)-induced increase of the intracellular cyclic adenosine monophosphate (cAMP) level. Cyclic AMP 217-221 androgen receptor Homo sapiens 42-59 9215398-1 1997 BACKGROUND: We investigated modulation of androgen receptor (AR) activity in prostatic tumor cells by luteinizing hormone-releasing hormone (LHRH)-induced increase of the intracellular cyclic adenosine monophosphate (cAMP) level. Cyclic AMP 217-221 androgen receptor Homo sapiens 61-63 9215398-3 1997 RESULTS: LHRH and cAMP derivative, respectively, induced reporter gene activity to about 15% of the maximal level in DU-145 cells transfected with an AR expression vector and an androgen-inducible reporter gene. Cyclic AMP 18-22 androgen receptor Homo sapiens 150-152 9215398-4 1997 LHRH or the cAMP analogue acted synergistically in combination with low concentrations of androgen thus lowering the androgen concentration required for maximal AR activation by a factor of 100. Cyclic AMP 12-16 androgen receptor Homo sapiens 161-163 9215398-5 1997 A similar activation of the AR by cAMP analogue was observed in LNCaP cells when enhancement of androgen-induced secretion of prostate-specific antigen was determined. Cyclic AMP 34-38 androgen receptor Homo sapiens 28-30 9215398-7 1997 CONCLUSIONS: The AR is synergistically activated by low doses of androgen and LHRH or the second messenger cAMP. Cyclic AMP 107-111 androgen receptor Homo sapiens 17-19 8925904-1 1996 A theoretical pathway of transcriptional regulation of the androgen receptor (AR) gene is via a cAMP response element (CRE) present in its promoter region (-508 to -501). Cyclic AMP 96-100 androgen receptor Homo sapiens 59-76 8925904-1 1996 A theoretical pathway of transcriptional regulation of the androgen receptor (AR) gene is via a cAMP response element (CRE) present in its promoter region (-508 to -501). Cyclic AMP 96-100 androgen receptor Homo sapiens 78-80 27133133-4 2016 In beta cells, DHT-activated AR is predominantly extranuclear and enhances GSIS by increasing islet cAMP and activating the protein kinase A. Cyclic AMP 100-104 androgen receptor Homo sapiens 29-31 8152432-7 1994 Deletion analysis of the AR gene promoter showed that a region between 530 bp and 380 bp upstream of AR gene transcription initiation site, which includes one potential cAMP response element (CRE), is responsible for cAMP induction. Cyclic AMP 169-173 androgen receptor Homo sapiens 25-27 8152432-7 1994 Deletion analysis of the AR gene promoter showed that a region between 530 bp and 380 bp upstream of AR gene transcription initiation site, which includes one potential cAMP response element (CRE), is responsible for cAMP induction. Cyclic AMP 169-173 androgen receptor Homo sapiens 101-103 8152432-7 1994 Deletion analysis of the AR gene promoter showed that a region between 530 bp and 380 bp upstream of AR gene transcription initiation site, which includes one potential cAMP response element (CRE), is responsible for cAMP induction. Cyclic AMP 217-221 androgen receptor Homo sapiens 25-27 8152432-7 1994 Deletion analysis of the AR gene promoter showed that a region between 530 bp and 380 bp upstream of AR gene transcription initiation site, which includes one potential cAMP response element (CRE), is responsible for cAMP induction. Cyclic AMP 217-221 androgen receptor Homo sapiens 101-103 34743733-10 2021 GV1001 enhanced the phosphorylation of AR and transcription activity of androgen response element reporter gene through cAMP/protein kinase A pathway. Cyclic AMP 120-124 androgen receptor Homo sapiens 39-41 30683712-7 2019 This centres on determining transcript levels for phosphodiesterase-4D7 (PDE4D7), an enzyme that breaks down cyclic AMP, a signalling molecule intimately connected with proliferation and androgen receptor function. Cyclic AMP 109-119 androgen receptor Homo sapiens 187-204 32881870-6 2020 Testosterone stimulation of GPR56 also activates the cAMP/ Protein kinase A (PKA) pathway, that is necessary for AR signaling. Cyclic AMP 53-57 androgen receptor Homo sapiens 113-115 23172223-4 2013 The cyclic AMP-induced increase in androgen-dependent and androgen-independent AR transcriptional activity correlated with an increase in MAGE-A11 and was inhibited by silencing MAGE-A11 expression. Cyclic AMP 4-14 androgen receptor Homo sapiens 79-81 23410945-1 2014 OBJECTIVES: In the present study, we investigated whether the cyclic adenosine monophosphate (cAMP)-activated protein kinase A (PKA) pathway may regulate the expression of AR and prostate-specific antigen (PSA) and whether there is a correlation between the expression of cAMP/PKA-associated genes and androgen receptor (AR) in patients with prostate cancer (CaP). Cyclic AMP 62-92 androgen receptor Homo sapiens 172-174 23410945-1 2014 OBJECTIVES: In the present study, we investigated whether the cyclic adenosine monophosphate (cAMP)-activated protein kinase A (PKA) pathway may regulate the expression of AR and prostate-specific antigen (PSA) and whether there is a correlation between the expression of cAMP/PKA-associated genes and androgen receptor (AR) in patients with prostate cancer (CaP). Cyclic AMP 94-98 androgen receptor Homo sapiens 172-174 23410945-1 2014 OBJECTIVES: In the present study, we investigated whether the cyclic adenosine monophosphate (cAMP)-activated protein kinase A (PKA) pathway may regulate the expression of AR and prostate-specific antigen (PSA) and whether there is a correlation between the expression of cAMP/PKA-associated genes and androgen receptor (AR) in patients with prostate cancer (CaP). Cyclic AMP 94-98 androgen receptor Homo sapiens 302-319 23410945-1 2014 OBJECTIVES: In the present study, we investigated whether the cyclic adenosine monophosphate (cAMP)-activated protein kinase A (PKA) pathway may regulate the expression of AR and prostate-specific antigen (PSA) and whether there is a correlation between the expression of cAMP/PKA-associated genes and androgen receptor (AR) in patients with prostate cancer (CaP). Cyclic AMP 94-98 androgen receptor Homo sapiens 321-323 23410945-5 2014 RESULTS: We showed that elevated levels of cAMP/PKA pathways induced an increased expression of AR and PSA proteins in LNCaP cells in the absence of androgen. Cyclic AMP 43-47 androgen receptor Homo sapiens 96-98 23410945-6 2014 A cAMP-associated phosphodiesterase-4 (PDE4) inhibitor, rolipram induced an up-regulation in AR expression, whereas a cAMP enhancer, forskolin increased PSA level without affecting AR expression. Cyclic AMP 2-6 androgen receptor Homo sapiens 93-95 23200735-5 2013 We also found that QT (50 muM) increased the expressions of AR and ER-alpha in the presence of a sub-threshold level of cyclic-AMP at 1h culture period to the levels seen with maximal stimulation of cyclic-AMP. Cyclic AMP 120-130 androgen receptor Homo sapiens 60-62 23200735-5 2013 We also found that QT (50 muM) increased the expressions of AR and ER-alpha in the presence of a sub-threshold level of cyclic-AMP at 1h culture period to the levels seen with maximal stimulation of cyclic-AMP. Cyclic AMP 199-209 androgen receptor Homo sapiens 60-62 23172223-9 2013 We conclude that the increased expression of MAGE-A11 in castration-recurrent prostate cancer, which is enhanced by cyclic AMP signaling, increases AR-dependent growth of prostate cancer by MAGE-A11 forming a molecular bridge between transcriptionally active AR dimers. Cyclic AMP 116-126 androgen receptor Homo sapiens 148-150 23172223-9 2013 We conclude that the increased expression of MAGE-A11 in castration-recurrent prostate cancer, which is enhanced by cyclic AMP signaling, increases AR-dependent growth of prostate cancer by MAGE-A11 forming a molecular bridge between transcriptionally active AR dimers. Cyclic AMP 116-126 androgen receptor Homo sapiens 259-261 15466214-3 2004 In AD LNCaP(nan) cells, dihydrotestosterone (DHT) stimulated in an androgen receptor (AR)-dependent way a phosphorylation signaling pathway involving steroid receptor coactivator (Src)-mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK)-1/2-ERK-1/2-cAMP-response element binding-protein (CREB). Cyclic AMP 280-284 androgen receptor Homo sapiens 67-84 19372581-0 2009 Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Cyclic AMP 108-118 androgen receptor Homo sapiens 24-41 19372581-7 2009 Cyclic AMP (cAMP) also increased MAGE-11 expression and AR transcriptional activity in prostate cancer cell lines. Cyclic AMP 0-10 androgen receptor Homo sapiens 56-58 19372581-7 2009 Cyclic AMP (cAMP) also increased MAGE-11 expression and AR transcriptional activity in prostate cancer cell lines. Cyclic AMP 12-16 androgen receptor Homo sapiens 56-58 19372581-9 2009 Increased expression of the AR coregulator MAGE-11 through promoter DNA hypomethylation and cAMP provides a novel mechanism for increased AR signaling in castration-recurrent prostate cancer. Cyclic AMP 92-96 androgen receptor Homo sapiens 28-30 19372581-9 2009 Increased expression of the AR coregulator MAGE-11 through promoter DNA hypomethylation and cAMP provides a novel mechanism for increased AR signaling in castration-recurrent prostate cancer. Cyclic AMP 92-96 androgen receptor Homo sapiens 138-140 15466214-3 2004 In AD LNCaP(nan) cells, dihydrotestosterone (DHT) stimulated in an androgen receptor (AR)-dependent way a phosphorylation signaling pathway involving steroid receptor coactivator (Src)-mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK)-1/2-ERK-1/2-cAMP-response element binding-protein (CREB). Cyclic AMP 280-284 androgen receptor Homo sapiens 86-88 15263086-5 2004 Androgen-mediated activation of mitogen-activated protein kinase and cAMP response element binding protein occurs within 1 min, extends for at least 12 h and requires AR. Cyclic AMP 69-73 androgen receptor Homo sapiens 167-169 15378487-1 2004 The androgen receptor co-activator CREB (cAMP-response element binding protein)-binding protein (CBP) enhances androgen receptor activity after stimulation by androgenic hormones and androgen receptor antagonists. Cyclic AMP 41-45 androgen receptor Homo sapiens 4-21 15378487-1 2004 The androgen receptor co-activator CREB (cAMP-response element binding protein)-binding protein (CBP) enhances androgen receptor activity after stimulation by androgenic hormones and androgen receptor antagonists. Cyclic AMP 41-45 androgen receptor Homo sapiens 111-128 15378487-1 2004 The androgen receptor co-activator CREB (cAMP-response element binding protein)-binding protein (CBP) enhances androgen receptor activity after stimulation by androgenic hormones and androgen receptor antagonists. Cyclic AMP 41-45 androgen receptor Homo sapiens 111-128 15123687-0 2004 The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity. Cyclic AMP 49-53 androgen receptor Homo sapiens 4-21